Brief: Medicenna Publishes Peer-Reviewed Preclinical Data On MDNA11 In The Journal For Immunotherapy Of Cancer

Medicenna Therapeutics

26/01/2022 12:42

Jan 26 (Reuters) - Medicenna Therapeutics Corp  MDNA.TO :
    * MEDICENNA ANNOUNCES PEER-REVIEWED PUBLICATION OF
PRECLINICAL
DATA ON MDNA11 IN THE JOURNAL FOR IMMUNOTHERAPY OF CANCER
    * MEDICENNA THERAPEUTICS CORP - MDNA11 DEMONSTRATES A
30-FOLD
INCREASE IN AFFINITY FOR IL-2 RECEPTOR BETA WITHOUT BINDING TO
IL-2 RECEPTOR ALPHA WHEN COMPARED TO RECOMBINANT HUMAN IL-2
    * MEDICENNA THERAPEUTICS CORP - MDNA11 WAS WELL-TOLERATED
AND
INDUCED DURABLE PROLIFERATION
    * MEDICENNA THERAPEUTICS CORP - MDNA11 ALONE OR IN
COMBINATION
WITH A CHECKPOINT INHIBITOR GENERATED DURABLE COMPLETE RESPONSES

Source text for Eikon:  ID:nGNX1fgtpM 
Further company coverage:  MDNA.TO 

 ((Reuters.Briefs@thomsonreuters.com;))